EFFECTS OF THE ANTIDEPRESSANT DRUG TIANEPTINE ON PLASMA AND PLATELET SEROTONIN OF DEPRESSIVE PATIENTS AND HEALTHY CONTROLS

被引:29
作者
ORTIZ, J
MARISCOT, C
ALVAREZ, E
ARTIGAS, F
机构
[1] CSIC, DEPT NEUROCHEM, E-08034 BARCELONA, SPAIN
[2] HOSP SANT PAU, DEPT PSYCHIAT, BARCELONA, SPAIN
关键词
SEROTONIN UPTAKE; PLASMA; PLATELETS; MAJOR DEPRESSIVE DISORDER; TIANEPTINE;
D O I
10.1016/0165-0327(93)90012-9
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We have examined the effects of a single 12.5 mg dose and of 12 weeks treatment up to 37.5 mg daily with tianeptine, a new antidepressant drug that potentiates in vivo the uptake of serotonin (5-HT). On day 0, tianeptine reduced plasma 5-HT concentration. This acute effect occurred also on subsequent examination days. However, long-term treatment tended (P<0.06) to increase basal plasma 5-HT concentrations, in covariation with decreases of MADRS (Montgomery-Asberg Depression Rating Scale) and HARS (Hamilton Anxiety Rating Scale). Platelet 5-HT increased only in elderly patients, probably due to the higher plasma concentration of the drug in this group than in younger patients. These results show that the acute effects of therapeutic doses of tianeptine are consistent with an enhancement of the 5-HT uptake. However, long-term treatment does not result in a decreased plasma 5-HT, as might be expected from the acute effects of the drug.
引用
收藏
页码:227 / 234
页数:8
相关论文
共 50 条
  • [21] Determinants of whole blood and plasma inertia in diabetic patients and healthy controls
    Mellinghoff, AC
    Reininger, AJ
    Landgraf, R
    Wurzinger, LJ
    Hepp, KD
    CLINICAL HEMORHEOLOGY, 1996, 16 (05): : 623 - 630
  • [22] Antidepressant effects of citalopram on treatment of alopecia areata in patients with major depressive disorder
    Abedini, Hossein
    Farshi, Susan
    Mirabzadeh, Arash
    Keshavarz, Saeed
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2014, 25 (02) : 153 - 155
  • [23] Shape and Volumetric Differences in the Corpus Callosum between Patients with Major Depressive Disorder and Healthy Controls
    Lee, Sekwang
    Pyun, Sung-Bom
    Choi, Kwan Woo
    Tae, Woo-Suk
    PSYCHIATRY INVESTIGATION, 2020, 17 (09) : 941 - 950
  • [24] Difference in proinflammatory cytokines produced by monocytes between patients with major depressive disorder and healthy controls
    Zhang, Hong-Xia
    Xu, Ye-Qing
    Li, Yuan-Yuan
    Lu, Ming-Fang
    Shi, Shen-Xun
    Ji, Jian-Lin
    Wang, Li-Wei
    JOURNAL OF AFFECTIVE DISORDERS, 2018, 234 : 305 - 310
  • [25] Cognitive factor structure and measurement invariance between healthy controls and patients with major depressive disorder
    Yang, Kai-Chun
    Hsieh, Wen-Chih
    Chou, Yuan-Hwa
    JOURNAL OF PSYCHIATRIC RESEARCH, 2022, 151 : 598 - 605
  • [26] RELATIONSHIP BETWEEN SEASONAL PATTERNS OF PLATELET SEROTONIN UPTAKE AND H-3 IMIPRAMINE BINDING IN DEPRESSED-PATIENTS AND NORMAL CONTROLS
    CHICZDEMET, A
    REIST, C
    DEMET, EM
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1991, 15 (01) : 25 - 39
  • [27] Effects of selective serotonin reuptake inhibitor treatment on plasma oxytocin and cortisol in major depressive disorder
    Charlotte Keating
    Tye Dawood
    David A Barton
    Gavin W Lambert
    Alan J Tilbrook
    BMC Psychiatry, 13
  • [28] Effects of selective serotonin reuptake inhibitor treatment on plasma oxytocin and cortisol in major depressive disorder
    Keating, Charlotte
    Dawood, Tye
    Barton, David A.
    Lambert, Gavin W.
    Tilbrook, Alan J.
    BMC PSYCHIATRY, 2013, 13
  • [29] Differences in Trauma Experience Between Patients With Bipolar I Disorder, Patients With Major Depressive Disorder, and Healthy Controls
    Kim, Hyun Joo
    Song, Wonyoung
    Park, Jae Woo
    JOURNAL OF TRAUMA & DISSOCIATION, 2015, 16 (04) : 419 - 427
  • [30] Association of plasma VEGF levels and the antidepressant effects of ketamine in patients with depression
    Zheng, Wei
    Zhou, Yan-Ling
    Wang, Cheng-Yu
    Lan, Xiao-Feng
    Zhang, Bin
    Zhou, Su-Miao
    Yan, Su
    Yang, Ming-Zhe
    Nie, Sha
    Ning, Yu-Ping
    THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2021, 11